Back to discover

Disease

Eosinophilia

Late-stage therapeutic developmentEmerging researchRising momentum

MeSHEosinophilia

3

Publications

12

Clinical trials

2

Related conditions

2016

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Research2016-04-11Blood

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Research2009-04-08Blood

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Research1985-10-01Annals of internal medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q4 2028.

Upcoming Milestones

Q4 2028Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

Major developments

Major trial resultsHigh impact

A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD

Results posted2026-04-24

Major clinical milestoneImportant

Treatment of Rhinosinusitis With Nasal Polyposis With Dupilumab and Mepolizumab: A Randomized, Multi-centre, Head-to-head Comparison in Real-world Danish Patients

Primary completion2026-04-01

Clinical Milestones4View

Results posted 1

2026-04-24A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPDResults posted

Results expected 1

2025-12-23Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic DisordersResults expected Q4 2028

Recently completed 2

2026-04-01Treatment of Rhinosinusitis With Nasal Polyposis With Dupilumab and Mepolizumab: A Randomized, Multi-centre, Head-to-head Comparison in Real-world Danish PatientsPrimary completion
2025-12-31Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic PatientPrimary completion

Activity timeline4

2026-04-24ClinicalA Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPDResults posted
2026-04-01ClinicalTreatment of Rhinosinusitis With Nasal Polyposis With Dupilumab and Mepolizumab: A Randomized, Multi-centre, Head-to-head Comparison in Real-world Danish PatientsPrimary completion
2025-12-31ClinicalComparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic PatientPrimary completion
2025-12-23ClinicalPhase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic DisordersResults expected Q4 2028

Clinical trials

10 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

12

All trials

3

Active

4

Late-stage

5

Completed

Late-stage studies

Treatment of Rhinosinusitis With Nasal Polyposis With Dupilumab and Mepolizumab: A Randomized, Multi-centre, Head-to-head Comparison in Real-world Danish Patients

Phase 4 · Active, not recruiting · Rigshospitalet, Denmark

Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

Phase 4 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES

Phase 3 · Completed · GlaxoSmithKline

A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD

Phase 2/3 · Completed · University of Leicester

Recruiting

Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient

N/A · Recruiting · Prince of Songkla University

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

Phase 2 · Recruiting · William Shomali

Recently completed

A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD

Phase 2/3 · Completed · University of Leicester

Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

Phase 4 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis: A Phase II Randomized Placebo Controlled Trial

Phase 2 · Completed · Johns Hopkins University

Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Phase 2 · Completed · Knopp Biosciences

A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES

Phase 3 · Completed · GlaxoSmithKline

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

19852016

Most influential

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood · 2016 · 6,456 cites

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Blood · 2009 · 3,044 cites

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Annals of internal medicine · 1985 · 1,644 cites

Recent publications

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood · 2016 · 6,456 cites

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Blood · 2009 · 3,044 cites

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Annals of internal medicine · 1985 · 1,644 cites

Leading journals2

Blood2
Annals of internal medicine1

Leading researchers8

Arber DA2
Bloomfield CD2
Borowitz MJ2
Le Beau MM2
Thiele J2
Vardiman JW2
Bennett JM1
Brunning RD1

Affiliations (unnormalised)6

University of Chicago2
Comprehensive Cancer Center1
Institute of Pathology1
John Hopkins Medical Institutions1
Massachusetts General Hospital1
Stanford University1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Myelodysplastic Syndromes2 Myeloproliferative Disorders2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Abnormal increase of EOSINOPHILS in the blood, tissues or organs.

Identifiers

MeSHEosinophilia

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.